Lecithin: Cholesterol acyltransferase, high-density lipoproteins, and atheroprotection in humans

Trends in Cardiovascular Medicine

Volumn 20, Issue 2, 2010, Pages 50-53

  Calabresi, Laura ^a   Franceschini, Guido ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; ENZYME ACTIVITY; GENE MUTATION; GENE OVEREXPRESSION; HEART PROTECTION; HUMAN; IN VIVO STUDY; MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; REVIEW;

ANIMALS; ATHEROSCLEROSIS; DISEASE MODELS, ANIMAL; HUMANS; LIPOPROTEINS, HDL; MACROPHAGES; MICE; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; RISK FACTORS;

EID: 77955058881     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tcm.2010.03.007     Document Type: Review

References (30)

1. Asztalos B.F., Schaefer E.J., Horvath K.V., et al. Role of LCAT in HDL remodeling: investigation of LCAT deficiency states. J Lipid Res 2007, 48:592-599.
2. Ayyobi A.F., McGladdery S.H., Chan S., et al. Lecithin: cholesterol acyltransferase (LCAT) deficiency and risk of vascular disease: 25 year follow-up. Atherosclerosis 2004, 177:361-366.
3. Berard A.M., Foger B., Remaley A., et al. High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase. Nat Med 1997, 3:744-749.
4. Brown B.G., Zhao X.Q., Chait A., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001, 345:1583-1592.
5. Calabresi L., Pisciotta L., Costantin A., et al. The molecular basis of lecithin:cholesterol acyltransferase deficiency syndromes: a comprehensive study of molecular and biochemical findings in 13 unrelated Italian families. Arterioscler Thromb Vasc Biol 2005, 25:1972-1978.
6. Calabresi L., Baldassarre D., Castelnuovo S., et al. Functional lecithin:cholesterol acyltransferase is not required for efficient atheroprotection in humans. Circulation 2009, 120:628-635.
7. Chen C.H., Albers J.J. Distribution of lecithin-cholesterol acyltransferase (LCAT) in human plasma lipoprotein fractions. Evidence for the association of active LCAT with low density lipoproteins. Biochem Biophys Res Commun 1982, 107:1091-1096.
8. Cuchel M., Rader D.J. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis?. Circulation 2006, 113:2548-2555.
9. Dullaart R.P., Perton F., Sluiter W.J., et al. Plasma lecithin:cholesterol acyltransferase activity is elevated in metabolic syndrome and is an independent marker of increased carotid artery intima media thickness. J Clin Endocrinol Metab 2008, 93:4860-4866.
10. Foger B., Chase M., Amar M.J., et al. Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice. J Biol Chem 1999, 274:36912-36920.
11. Frohlich J., Dobiasova M. Fractional esterification rate of cholesterol and ratio of triglycerides to HDL-cholesterol are powerful predictors of positive findings on coronary angiography. Clin Chem 2003, 49:1873-1880.
12. Furbee J., Parks J. Transgenic overexpression of human lecithin: cholesterol acyltransferase (LCAT) in mice does not increase aortic cholesterol deposition. Atherosclerosis 2002, 165:89-100.
13. Glomset J.A. The plasma lecithin:cholesterol acyltransferase reaction. J Lipid Res 1968, 9:155-162.
14. Hoeg J.M., Santamarina-Fojo S., Berard A.M., et al. Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis. Proc Natl Acad Sci U S A 1996, 93:11448-11453.
15. Holleboom A.G., Kuivenhoven J.A., Vergeer M., et al. Plasma levels of lecithin:cholesterol acyltransferase and risk of future coronary artery disease in apparently healthy men and women: a prospective case-control analysis nested in the EPIC-Norfolk population study. J Lipid Res 2010, 51:416-421.
16. Hovingh G.K., Hutten B.A., Holleboom A.G., et al. Compromised LCAT function is associated with increased atherosclerosis. Circulation 2005, 112:879-884.
17. Ji Y., Wang N., Ramakrishnan R., et al. Hepatic scavenger receptor BI promotes rapid clearance of high density lipoprotein free cholesterol and its transport into bile. J Biol Chem 1999, 274:33398-33402.
18. Jonas A. Lecithin cholesterol acyltransferase. Biochim Biophys Acta 2000, 1529:245-256.
19. Lambert G., Sakai N., Vaisman B.L., et al. Analysis of glomerulosclerosis and atherosclerosis in lecithin:cholesterol acyltransferase-deficient mice. J Biol Chem 2001, 276:15090-15098.
20. Nakamura Y., Kotite L., Gan Y., et al. Molecular mechanism of reverse cholesterol transport: reaction of pre-beta-migrating high-density lipoprotein with plasma lecithin/cholesterol acyltransferase. Biochemistry 2004, 43:14811-14820.
21. Ng D.S., Maguire G.F., Wylie J., et al. Oxidative stress is markedly elevated in lecithin:cholesterol acyltransferase-deficient mice and is paradoxically reversed in the apolipoprotein E knockout background in association with a reduction in atherosclerosis. J Biol Chem 2002, 277:11715-11720.
22. Rousset X., Vaisman B., Amar M., et al. Lecithin:cholesterol acyltransferase-from biochemistry to role in cardiovascular disease. Curr Opin Endocrinol Diabetes Obes 2009, 16:163-171.
23. Rye K.A., Barter P.J. Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler Thromb Vasc Biol 2004, 24:421-428.
24. Schwartz C.C., Vlahcevic Z.R., Berman M., et al. Central role of high density lipoprotein in plasma free cholesterol metabolism. J Clin Invest 1982, 70:105-116.
25. Schwartz C.C., VandenBroek J.M., Cooper P.S. Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans. J Lipid Res 2004, 45:1594-1607.
26. Solajic Bozicevic N., Stavljenic A., Sesto M. Lecithin:cholesterol acyltransferase activity in patients with acute myocardial infarction and coronary heart disease. Artery 1991, 18:326-340.
27. Solajic-Bozicevic N., Stavljenic-Rukavina A., Sesto M. Lecithin-cholesterol acryltransferase activity in patients with coronary artery disease examined by coronary angiography. Clin Investig 1994, 72:951-956.
28. Stein J.H., Korcarz C.E., Hurst R.T., et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr 2008, 21:93-111.
29. Tanigawa H., Billheimer J.T., Tohyama J.I., et al. Lecithin:cholesterol acyltransferase expression has minimal effects on macrophage reverse cholesterol transport in vivo. Circulation 2009, 120:160-169.
30. Wells I.C., Peitzmeier G., Vincent J.K. Lecithin: cholesterol acyltransferase and lysolecithin in coronary atherosclerosis. Exp Mol Pathol 1986, 45:303-310.